Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2012

View Archived Issues

GABAergic compound shows early promise in improving fragile X symptoms

Phase II trial begins for molecular imaging drug for prostate cancer

Amakem begins phase IIa AMA-0076 trial

University of Chicago designs novel anti-staphylococcal agents

Research at the University of Pennsylvania yields new cancer biotherapeutics

Novel AMPK activators disclosed in GSK patent

Seebri Breezhaler approved for COPD maintenance treatment in Japan

New York University presents new PGRN variants for inflammation

Pfizer obtains approval for Tygacil in Japan

Further clinical data reported on cancer vaccine MGN-1601 at ESMO

Neuralstem cleared to study NSI-566 in China

Novel BACE1 inhibitors created at Janssen Pharmaceutica

Phase I data on veliparib in patients with brain metastases reported

Roche presents new antidiabetic compounds

Dainippon Sumitomo Pharma obtains approval for Aimix combination tablets

Ariad completes rolling NDA submission for ponatinib

Novartis obtains Japanese approval for tobramycin

FDA expands approval of Venofer to pediatric patients

Phase III trial of OncoGenex' lead candidate commences in advanced NSCLC

Stem cell gene therapy shows promise in mucopolysaccharidosis IIIA model

Vital Therapies closes first stage of financing to fund phase III program for Elad

Osiris Therapeutics regains rights to Prochymal and Chondrogen

StemCells gives update on phase I/II chronic spinal cord injury study

Teva acquires Huntexil development program rights from NeuroSearch

Zosyn receives new indication approvals in Japan

Lotriga approved in Japan for the treatment of hyperlipidemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...